Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biopharmaceutical company focused on developing targeted therapies, including antibody-drug conjugates, for cancer patients who do not respond to, or have disease progression on, current treatments. The NXTC news feed highlights company announcements that trace the progress of its pipeline and corporate strategy.
Investors and followers of NextCure can use this page to review updates on its lead ADC programs, SIM0505 and LNCB74. News items include business updates and quarterly financial results, where the company discusses clinical trial status, dose escalation progress and plans for proof-of-concept data readouts in advanced solid tumors. Press releases also cover preclinical findings for programs such as NC605 in osteogenesis imperfecta and NC181 in Alzheimer’s disease models.
NXTC news frequently addresses strategic partnerships and licensing agreements, such as the collaboration with Simcere Zaiming for SIM0505 and the co-development arrangement with LigaChem Biosciences Inc. for LNCB74. Readers will also find coverage of scientific presentations at major conferences, including trial-in-progress posters and preclinical data presentations.
In addition, the feed includes capital markets and corporate developments reported by NextCure, such as private placements of common stock and pre-funded warrants, reverse stock split implementation, and changes in executive leadership. These disclosures provide context on how the company finances its research and manages its listing on the Nasdaq Global Select Market.
By reviewing the NXTC news page regularly, users can follow the evolution of NextCure’s oncology-focused pipeline, its non-oncology preclinical efforts, and key corporate decisions that may influence the company’s development plans and financial position.
NextCure has published preclinical data on NC410, a novel immunomedicine targeting collagen-rich tumors, in the journal eLife. This treatment, currently in a Phase 1/2 clinical trial for advanced solid tumors, aims to block immune suppression via LAIR-1. Preclinical studies show that NC410 promotes T cell activity and may be effective as a monotherapy or in combination with checkpoint inhibitors. Initial clinical data is expected in the second half of 2021, offering potential hope for patients with resistant cancers.
NextCure, Inc. (Nasdaq: NXTC) announced its participation in a fireside chat at the JMP Securities Life Sciences Conference on June 17 at 1:30 pm Eastern time. Interested investors can access the live audio webcast on its website, with a replay available afterward for 30 days. NextCure is focused on developing first-in-class immunomedicines to treat cancer and other immune-related diseases through its proprietary FIND-IO™ platform, aiming to provide new treatments for patients resistant to current therapies.
NextCure, a clinical-stage biopharmaceutical company, announced that Dr. Martin Gutierrez will present a Trials in Progress poster for NC410 at the 2021 ASCO Annual Meeting. NC410 targets collagen-rich areas in tumors, acting as a LAIR-1 decoy to enhance immune responses. Preliminary studies indicate significant anti-tumor activity across multiple cancer types, including gastric and ovarian cancers. The Phase 1/2 study aims to assess safety and preliminary efficacy, with initial clinical data expected in late 2021.
NextCure, Inc. (Nasdaq: NXTC) reported its Q1 2021 financial results, showing a net loss of $16.5 million compared to a net income of $9.7 million in Q1 2020. The company’s cash reserves decreased to $268.2 million, down from $283.4 million at year-end 2020, impacted by operational expenditures. Notably, no revenue was generated in Q1 2021, a decline from $22.4 million the previous year. The company remains focused on its clinical programs, with ongoing trials for NC318, NC410, and NC762, and expects to fund operations into the second half of 2023.
NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 12 at 2:00 pm ET. The event will showcase NextCure's commitment to developing innovative immunomedicines for cancer and immune-related diseases, leveraging their proprietary FIND-IO™ platform. A live audio webcast will be accessible via their website, with a replay available for 30 days post-event.
NextCure, Inc. (Nasdaq: NXTC) announced its participation in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5th at 2:40 PM Eastern time. The event will be accessible via a live audio webcast on the company’s website, with a replay available for 30 days post-event.
NextCure focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its FIND-IO™ platform. The company aims to provide new treatments for patients unresponsive to existing therapies.
NextCure (Nasdaq: NXTC) presented preclinical data for its investigational monoclonal antibody NC762 at the AACR Annual Meeting 2021. NC762 targets B7-H4, showing promising anti-tumor properties and inhibiting tumor growth in various cancer models. Key findings include a mechanism of action independent from T cells and NK cells, allowing for enhanced anti-tumor activity. IND-enabling studies showed a favorable safety profile and half-life of 8-10 days. NextCure plans to advance NC762 into clinical trials this quarter, aiming to expand its innovative immunomedicine pipeline.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 13 at 12:45 PM Eastern Time. The company focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. A live audio webcast will be accessible on the company's website, with a replay available for 30 days post-event.
NextCure, Inc. (Nasdaq: NXTC) reported its financial results for Q4 and full year 2020, including a net loss of $36.6 million for the year, reflecting a rise in R&D and G&A expenses. Cash reserves decreased from $334.6 million in 2019 to $283.4 million in 2020. Despite challenges from the COVID-19 pandemic, the company is advancing clinical trials for NC318, including a Phase 2 trial planned at Yale University. NextCure is also preparing to initiate trials for NC762 and anticipates sharing initial data for NC410 in the second half of 2021.
NextCure, Inc. (Nasdaq: NXTC) will host a Virtual R&D Update Event on March 4 at 5:00 p.m. ET. Interested participants can listen via a conference call or webcast through NextCure's website. The U.S. toll-free dial-in number is (877) 665-6632, or (602) 563-8471 internationally, using Conference ID 6773907. A replay will be available two hours after the event and archived for 30 days. NextCure focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform.